0001662002-15-000001.txt : 20151229 0001662002-15-000001.hdr.sgml : 20151229 20151229170612 ACCESSION NUMBER: 0001662002-15-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20151229 DATE AS OF CHANGE: 20151229 EFFECTIVENESS DATE: 20151229 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nohla Therapeutics Inc. CENTRAL INDEX KEY: 0001662002 IRS NUMBER: 475261773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-254087 FILM NUMBER: 151311788 BUSINESS ADDRESS: STREET 1: 1616 EASTLAKE AVENUE EAST STREET 2: SUITE 202 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 61430589444 MAIL ADDRESS: STREET 1: 1616 EASTLAKE AVENUE EAST STREET 2: SUITE 202 CITY: SEATTLE STATE: WA ZIP: 98102 D 1 primary_doc.xml X0707 D LIVE 0001662002 Nohla Therapeutics Inc. 1616 EASTLAKE AVENUE EAST SUITE 202 SEATTLE WA WASHINGTON 98102 61430589444 DELAWARE Cytomatrix Therapeutics, Inc. None Corporation true 2015 Benjamin Scot Bergo 1616 Eastlake Avenue East Suite 202 Seattle WA WASHINGTON 98102 Executive Officer Director Promoter Ian David Brown 1616 Eastlake Avenue East Suite 202 Seattle WA WASHINGTON 98102 Director Lawrence Gozlan 1616 Eastlake Avenue East Suite 202 Seattle WA WASHINGTON 98102 Director Darren Scotti 1616 Eastlake Avenue East Suite 202 Seattle WA WASHINGTON 98102 Executive Officer Biotechnology Decline to Disclose 06b false 2015-12-15 false true false 0 2024998 2024998 0 The Company offered and sold securities totaling $21,149,994 in the financing. The offer and sale of the remaining securities was exempt from registration pursuant to Regulation S promulgated under the Securities Act of 1933, as amended. false 9 0 0 0 false Nohla Therapeutics Inc. /s/ Darren Scotti Darren Scotti Secretary 2015-12-29